Medicenna, a clinical-stage immunotherapy company, has made significant progress in developing its therapies MDNA11 and MDNA55, which utilize engineered interleukins, known as Superkines, to modulate the immune system and combat challenging diseases like recurrent glioblastoma multiforme (rGBM) – an invariably fatal form of brain cancer and other end stage cancers.
MDNA55, an empowered Superkine, delivers a potent bacterial toxin directly to tumor cells using a highly specific IL-4 cytokine as a vehicle. By doing so, it has the potential to purge bulk tumors, disrupt their supporting networks, and reactivate the immune system to combat cancer.
In this exclusive interview, DocWire News spoke with Fahar Merchant, Ph.D., President and CEO of Medicenna, about MDNA55 treatment and clinical trial results which highlight its promising impact on glioblastoma patient survival. #glioblastoma #GMB #braincancer
